Articles related to BUSINESS & POLICY

New data suggests that the Galleri blood test’s sensitivity for early-stage cancers may be lower than initially reported, potentially limiting its utility as a screening tool.

Prostate cancer screening guidelines that use race as a criterion are under ethical scrutiny, with experts calling for a shift towards universal, unbiased risk assessment that addresses socioeconomic factors and healthcare access disparities.

The annual cost of cancer screening represents a notable portion of overall U.S. health care system costs related to cancer, with private insurance covering the majority of expenses.

MCED tests aim to detect multiple cancer types through a single blood test, potentially simplifying cancer screening and expanding detection capabilities. However, their implementation raises critical questions about evidence standards and evaluation methods.

PBMs’ vertical integration allows them to dictate cancer treatment decisions, from drug selection to delivery methods, potentially compromising patient care and increasing costs.

The inclusion of Medicare Advantage data and increased emphasis on patient outcomes in the US News Best Hospitals rankings further illustrates the growing importance of comprehensive, coordinated care in today’s healthcare landscape.